Bought Genmab (GMAB)...Biotech in Denmark

C

Cabin111

Just 100 shares in my trust...Then did a covered call.

Bought at $39.21, then did a covered call (sell to open) for the 8/18/23 $40.00...I got $4.20 ($420.00) for the option.

Over the weekend I looked up companies with a "wide moat"...This one popped up. I looked into it. They have existing products, good partners, and a good/fair pipeline. They also make money...ADR, boring but I can do options on it.
 
There is nothing about GMAB fundamentals/technicals in your thread.


You should put this thread in your Journal

and not creating unnecessary new threads every time you create an order.
 
Last edited:
JonLivingston said:
How did you look up companies with "wide moat" and how did you "look into it" if you don't mind me asking?
More...

I didn't totally believe this...I looked further. Again, I liked the pipeline, they make money, partnerships, options, and location.

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwit98CCuKj9AhUyMjQIHXlFCxEQnLoEegQIDBAB&url=https://www.nasdaq.com/stocks/investing-lists/wide-moat-companies&usg=AOvVaw2ZLWI40fxr2clgplciV3qX

PS I had about $5,000. something to invest...
 
Introduction

Genmab is a biopharmaceutical company based in Copenhagen, Denmark. The company is focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer and other serious diseases. Genmab was founded in 1999 and is listed on the Copenhagen Stock Exchange. The company has over 500 employees and has operations in Europe, the United States, and Asia.

Research and Development

Genmab has a wide range of research and development activities, with a focus on the development of novel antibody-based therapies. The company has a number of partnerships with leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Merck, and Novartis. Genmab has a number of clinical stage programs, including Daratumumab, a monoclonal antibody for the treatment of multiple myeloma, and Ofatumumab, an anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Genmab also has a number of preclinical programs in various stages of development.

Products

Genmab has two marketed products, Daratumumab and Ofatumumab. Daratumumab is a monoclonal antibody for the treatment of multiple myeloma. The drug was approved by the FDA in November 2015 and is currently being marketed in the United States, Europe, and Japan. Ofatumumab is an anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. The drug was approved by the FDA in October 2009 and is currently being marketed in the United States, Europe, and Japan.

Financials

Genmab has a market capitalization of approximately $9.5 billion. The company reported revenues of $869 million in 2019, with net income of $408 million. Genmab’s cash and cash equivalents stood at $1.3 billion as of December 31, 2019.

Conclusion

Genmab is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer and other serious diseases. The company has two marketed products, Daratumumab and Ofatumumab, and a number of clinical and preclinical programs in various stages of development. Genmab has a market capitalization of approximately $9.5 billion and reported revenues of $869 million in 2019.
 
Genmab's competitive advantage lies in its focus on developing innovative therapies that target unmet medical needs. The company has a strong pipeline of products in development, with a focus on novel antibody-based therapies for cancer, autoimmune diseases, and other serious illnesses. Genmab also has an experienced management team and a strong track record of successful collaborations with large pharmaceutical companies. These collaborations have enabled Genmab to access the resources and expertise needed to develop and commercialize its products.
 
You must log in or register to reply here.
Back
Top